A 2026 ECG analysis involving 269 healthy young adults found that sex differences in resting heart-rate dynamics appeared in very short 2-5 second fluctuations, not in the usual 5-minute heart rate variability averages. The short-window similarity graph metric predicted male sex with an odds ratio of 2.78 (95% CI 1.32-5.86), while conventional lnRMSSD, lnHF-HRV, and …
A 2026 serum multiomics study linked occupational noise exposure to tinnitus severity mostly through metabolism: 10 metabolites, including GABA, fumaric acid, and steroid hormone precursors, statistically mediated 92% of the exposure-tinnitus association.1 The result is not a clinical blood test yet, but it pushes tinnitus biology beyond the ear-only frame toward a metabolism-immunity model that …
A 2026 single-cell and spatial-transcriptomics study of 21,156 brain immune cells found that late amyloid disease shifted interferon-driven neuroinflammation from microglia toward plaque-associated CD8 T cells, with T-cell frequency strongly tracking total amyloid deposits (Spearman rho = 0.844, p < 0.0001).1 The result does not turn Alzheimer’s disease into an autoimmune disease, but it makes …
A 2026 prospective birth-cohort study in southern China linked mean cord-blood lead of 15.30 μg/L to lower infant neurodevelopmental scores across all 5 Ages and Stages Questionnaire domains, even though only 1.13% of samples exceeded 50 μg/L.1 A second finding was mechanistic: part of the lead-development association statistically ran through FAM50B/PTCHD3 DNA methylation, an epigenetic …
A 2026 pilot randomized trial in 16 frail adults with multiple sclerosis found that 6 weeks of supervised multimodal exercise was feasible: retention was 87.5%, adherence was 97.2%, no adverse events were recorded, and fatigue and quality-of-life scores moved more than they did with waitlist control.1 Research Highlights Feasibility cleared the prespecified bar: 14 of …
A 2026 Medicare target-trial emulation found continued levetiracetam after acute ischemic stroke was associated with 53 vs. 62 deaths per 1,000 over 90 days, a risk difference of −9 deaths per 1,000 favoring continuation. Research Highlights Survival signal: continued levetiracetam after an initial month of post-stroke use was linked to 53 deaths per 1,000 vs. …
A 2026 medRxiv preprint found that a training-free speech biomarker tracked dysarthria severity across 890 speakers, 10 corpora, and 5 full-pipeline languages, with all 5 consonant d-prime features showing random-effects correlations with clinical severity (rho = −0.50 to −0.56; all p < 2e−4). Research Highlights Speech-severity signal was broad: Muller et al. evaluated 890 speakers …